Thinning bone and inhaled corticosteroid in COPD: What to do until there is definitive proof?

Chest

Volumn 136, Issue 6, 2009, Pages 1448-1449

  Paul Man, S F ^a   Sin, Don D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL;

BONE DEMINERALIZATION; BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG SAFETY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; FRACTURE; HEALTH CARE COST; HIP; HUMAN; LUMBAR SPINE; NUTRITION; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; SMOKING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 73149104382     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-1787     Document Type: Editorial

References (6)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555
2. Robbins J, Aragaki AK, Kooperberg C, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA 2007; 298:2389-2398
3. Mundy GR. Osteoporosis and inflammation. Nutr Rev 2007; 65:S147-S151
4. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from TORCH. Chest 2009; 136:1456-1465
5. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789
6. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:1207-1214